Our 2023 Event has Concluded

2023’s Members of the Judiciary
Speaker

Honorable Leonard P. Stark

United States Judge
U.S. Court of Appeals for the Federal Circuit
(Former Chief Judge, United States District Court, District of Delaware)

Speaker

Honorable Stanley R. Chesler

District Judge
United States District Court, District of New Jersey

Speaker

Honorable Maryellen Noreika

District Judge
United States District Court, District of Delaware

Speaker

Honorable Mitchell Goldberg

District Judge
United States District Court, Eastern District of Pennsylvania
(Visiting Judge, District of Delaware)

Speaker

Honorable Joshua Wolson

District Judge
United States District Court

Eastern District of Pennsylvania
(Visiting Judge, District of Delaware)

Speaker

Honorable Christopher J. Burke

Magistrate Judge
District of Delaware

2023 Government Representatives from U.S. Patent and Trademark Office
Speaker

Honorable Jacqueline Bonilla

Deputy Chief Administrative Patent Judge, Patent Trial & Appeal Board
U.S. Patent and Trademark Office

Speaker

Honorable Susan Mitchell

Lead Judge, Patent Trial & Appeal Board
U.S. Patent and Trademark Office

Speaker

Honorable Grace Obermann

Administrative Patent Judge, Patent Trial & Appeal Board
U.S. Patent and Trademark Office

2023 Co-Chairs
Speaker

Honorable Kathleen M. O’Malley (Ret.)

Of Counsel
Irell & Manella LLP
(Former United States Circuit Judge U.S. Court of Appeals for the Federal Circuit)

Speaker

Neema Kumar

Vice President, IP, North America
Sandoz

Speaker

Serena Farquharson Torres

Executive Director, Assistant General Counsel
Bristol Myers Squibb

“This year’s Paragraph IV Disputes conference comes at an important time. Our innovation and IP Ecosystem are under attack from a variety of sources, putting our economy, the future of our health care, and our strategic place in the world at risk. I look forward to discussing these risks and possible ways to minimize those risks with the talented pool of IP professionals the conference annually brings together.

I am also personally pleased that I am being given the chance to conduct a dialogue with Judge Leonard Stark, my successor on the Federal Circuit. That will be a highlight of the Conference for me.”

— Honorable Kathleen M. O’Malley (Ret.)

“A robust and predictable patent system is critical to incentivizing innovation while facilitating access and ensuring the long-term sustainability of lower cost critical medicines. Join industry leaders, members of the judiciary, key agency representatives and your colleagues as we discuss game changing legislation impacting our industry and patients, current Hatch-Waxman trends, pharmaceutical policy initiatives and much more.”

— Neema Kumar

“Being on the forefront of pioneering research makes me both excited and hopeful for our patients yet somehow uncertain of the future protection of such innovation. I’m looking forward to hearing from government agencies, the judiciary, in-house and outside counsel regarding various considerations impacting the future of patent procurement as well as patent enforcement.”

— Serena Farquharson Torres

A REVIEW OF ACI’s PARAGRAPH IV DISPUTES CONFERENCES

3,700+

Attendees

560+

Speakers

110+

Sponsors

DISTINGUISHED FACULTY

The best that the bar, the bench, and the industry have to offer

MASTER LEVEL STRATEGIES

For litigators and in-house counsel

UNPARALLELED CONNECTIONS

With the “Who’s Who” of Hatch-Waxman litigators


Join the conference that the “who’s who” of Hatch-Waxman litigators have designated as the forum which sets the standards for Paragraph IV practice.

Since 2006, when we launched our inaugural conference, pharmaceutical patent practitioners from throughout the country and in some instances across the globe have attended this conference to confer with each other and assess the implications and imprimaturs of court cases, legislation, and industry behaviors which affect the patent endgame and the pursuit of related profits. They also come to hear from Judges — both from the federal judiciary, and U.S. P.T.O.’s PTAB — the FTC, and the FDA.

Leaders from both brand and generic drug companies recognize that this event is the single forum which serves both sides of the industry and is second to none in offering both legal and economic “take aways” for every sphere of this costly, complex and evolving litigation. This is the only event on market which not only addresses the hot topics, but also puts them within the context of pre-suit considerations, case filings, final adjudication and every step in between. This unique dynamic exemplifies not only the importance of the content and legal theory presented, but the contending business acuities as well.

We invite you to join us at this flagship event to get caught up on legal developments and learn how your peers (and opponents) are navigating the ever-changing landscape.